Acalabrutinib in patients with mantle cell lymphoma subjected to allogeneic hematopoietic cell transplantation. a phase 2 study by the Polish Lymphoma Research Group
This phase 2 trial evaluated the safety and efficacy of acalabrutinib used to reduce tumor burden before allogeneic hematopoietic cell transplantation (allo‑HCT) and as a maintenance therapy after transplantation in patients with relapsed/refractory mantle cell lymphoma (R/R MCL).
This phase 2 trial evaluated the safety and efficacy of acalabrutinib used to reduce tumor burden before allogeneic hematopoietic cell transplantation (allo‑HCT) and as a maintenance therapy after transplantation in patients with relapsed/refractory mantle cell lymphoma (R/R MCL).
The study demonstrates that a second‑generation Bruton tyrosine kinase inhibitor can serve as an effective bridge to allo‑HCT and as a post‑transplant maintenance agent, potentially improving response rates and long‑term outcomes in relapsed/refractory mantle cell lymphoma.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Mantle Cell Lymphoma: Are New Therapies Changing the Standard of Care?
- Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology
- Refining risk stratification for mantle cell lymphoma: integrating novel combination treatments and personalized approaches.
- Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma
- Hairy Cell Leukemia: Clinical Characteristics and Outcomes from a Single Center in the Middle East and North Africa